Advertisement
LYEL vs VCYT
Which Stock Would AI Choose? Lyell Immunopharma (LYEL) vs. Veracyte (VCYT) Stock Comparison
Key Takeaways
- LYEL is a clinical-stage biotech developing next-generation CAR T-cell therapies (engineered immune cells designed to attack cancer), while VCYT is a profitable, revenue-generating cancer diagnostics company.
- Veracyte reported solid recent results and raised its full-year guidance, whereas Lyell remains pre-revenue with losses narrowing as it advances its clinical pipeline.
- Lyell carries higher volatility and binary clinical-catalyst risk; Veracyte offers steadier fundamentals but faces reimbursement and commercialization execution risks.
- Market positioning diverges sharply: Lyell trades near its cash position with significant short interest, while Veracyte commands a premium valuation supported by positive earnings.
Introduction
Investors weighing oncology-focused growth opportunities often encounter two very different profiles. LYEL, Lyell Immunopharma, is a clinical-stage biotechnology company developing cell therapies, a field defined by high scientific promise and substantial binary risk. VCYT, Veracyte, is a global diagnostics company already generating meaningful revenue and profits from genomic cancer tests. This stock comparison examines relative performance, market positioning, and the factors shaping sentiment, offering a useful reference for traders assessing risk-tolerant biotech exposure against more established, cash-generating healthcare businesses.
LYEL Overview and Recent Performance
Lyell Immunopharma is a late-stage clinical company focused on next-generation chimeric antigen receptor (CAR) T-cell therapies for cancer. Its lead candidate, ronde-cel, is a dual-targeting CD19/CD20 therapy for large B-cell lymphoma (LBCL), a cancer of the lymphatic system. Recent weeks have brought several catalysts: the company closed a $50 million tranche of an equity placement tied to a clinical milestone and secured regenerative medicine advanced therapy (RMAT) designation from the FDA (Food and Drug Administration), a status intended to speed development of promising therapies.
Financially, Lyell reported a first-quarter net loss that narrowed meaningfully year over year while maintaining a cash position of roughly $261 million. Revenue remains negligible, consistent with its pre-commercial stage. The stock has experienced notable price swings, with some periods of sharp decline that pushed shares into technically oversold territory, alongside high short interest relative to its public float. Sentiment has been shaped by upcoming data readouts, with additional trial data expected in the second half of the year and a planned biologics license application (BLA) filing targeted for mid-2027.
VCYT Overview and Recent Performance
Veracyte is a global diagnostics company whose platform delivers genomic tests that help clinicians diagnose and guide treatment decisions across several cancers. Its core franchises include Afirma for thyroid cancer and Decipher Prostate for prostate cancer, supported by newer launches such as Prosigna for breast cancer and TrueMRD for bladder cancer recurrence monitoring.
Recent performance has been characterized by double-digit testing volume and revenue growth. Veracyte reported first-quarter revenue of approximately $139 million and GAAP (generally accepted accounting principles) net income of about $28.7 million, and subsequently raised its full-year revenue guidance to a range of $582 million to $592 million. The company holds a substantial cash balance with no current debt. Despite these fundamentals, the stock has seen periods of selling pressure tied to reimbursement uncertainty and early-stage launch execution, even as analysts have revised earnings estimates higher. New clinical data supporting its Decipher Prostate test and expanded clinical guidelines have acted as additional drivers of sentiment.
Trending AI Robots
For traders seeking a systematic approach to opportunities like these, Tickeron's Trending AI Robots page curates a focused selection of AI trading bots. Tickeron hosts hundreds of AI-powered trading bots that collectively monitor thousands of tickers, but only the strongest performers suited to current market conditions earn a place in this trending section. These bots span diverse trading styles, strategies, timeframes, and performance statistics, each with its own set of tickers it trades. Because no two bots are identical, the curated list helps users identify approaches that align with the prevailing market environment. Explore the Trending AI Robots to review current selections and performance metrics.
Head-to-Head Comparison
The clearest contrast between these two names is maturity. Lyell is pre-commercial, with minimal revenue and a valuation heavily tied to the success of its clinical pipeline and its available cash. Veracyte, by contrast, generates hundreds of millions in annual revenue, is profitable, and operates with a debt-free balance sheet. This translates into different risk profiles: Lyell's share price can move sharply on a single clinical or regulatory update, while Veracyte's moves are more closely linked to test volume, reimbursement decisions, and launch execution.
Growth drivers also differ. Lyell's thesis rests on binary catalysts such as pivotal trial data and a future regulatory filing. Veracyte's growth is more diversified, spanning established tests, new product launches, and international expansion, though it remains concentrated in a few core assays. Sector exposure overlaps through oncology, but Lyell sits in speculative biotech while Veracyte belongs to diagnostics. On relative performance, Veracyte has shown more stable, earnings-supported movement, whereas Lyell has been more volatile, with deeper drawdowns and higher short interest relative to its float.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor VCYT in the current environment. The diagnostics company demonstrates more consistent trend characteristics, positive earnings, a stronger balance sheet, and multiple, non-binary catalysts. LYEL presents higher potential upside tied to clinical milestones, but its price action is more volatile and its path is more dependent on single events. This assessment reflects relative positioning rather than a definitive forecast, and the balance could shift as Lyell approaches its upcoming data readouts and as Veracyte executes on new launches and reimbursement coverage.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LYEL is a StrongBuy and VCYT is a StrongBuy.
LYEL in upward trend: price rose above 50-day moving average on October 29, 2026
LYEL moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend. In 36 of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on LYEL as a result. In 74 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for LYEL just turned positive on October 15, 2026. Looking at past instances where LYEL's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.
Following a +11.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where LYEL advanced for three days, in 201 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The 10-day RSI Indicator for LYEL moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 19 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LYEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
LYEL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LYEL entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. LYEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.157) is normal, around the industry mean (3.154). P/E Ratio (-0.870) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. LYEL's P/S Ratio (10000.000) is very high in comparison to the industry average of (439.237).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LYEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VCYT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for VCYT turned positive on October 21, 2026. Looking at past instances where VCYT's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VCYT as a result. In 79 of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
VCYT moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VCYT crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +3.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 204 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The 10-day RSI Indicator for VCYT moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 26 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
VCYT broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. VCYT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.896) is normal, around the industry mean (65.853). P/E Ratio (34.729) is within average values for comparable stocks, (2.707). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
VCYT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 86 | |
SMR RATING 1..100 | 75 | |
PRICE GROWTH RATING 1..100 | 38 | |
P/E GROWTH RATING 1..100 | 94 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| LYEL | VCYT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 86% | 2 days ago 76% |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 82% |
| TrendWeek ODDS (%) | 2 days ago 84% | 2 days ago 75% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 81% |
| Advances ODDS (%) | 3 days ago 84% | 3 days ago 73% |
| Declines ODDS (%) | 10 days ago 89% | 19 days ago 79% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 90% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LYEL’s FA Score shows that 1 FA rating(s) are green while VCYT’s FA Score has 0 green FA rating(s).
- LYEL’s FA Score: 1 green, 4 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LYEL’s TA Score shows that 4 TA indicator(s) are bullish while VCYT’s TA Score has 5 bullish TA indicator(s).
- LYEL’s TA Score: 4 bullish, 5 bearish.
- VCYT’s TA Score: 5 bullish, 4 bearish.
Price Growth
LYEL (@Biotechnology) experienced а +17.57% price change this week, while VCYT (@Medical Specialties) price change was +4.34% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +2.12%. For the same industry, the average monthly price growth was -4.89%, and the average quarterly price growth was +48.45%.
Reported Earning Dates
LYEL is expected to report earnings on Nov 11, 2026.
VCYT is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (+0.20% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (+2.12% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
LYEL and
Correlation & Price change
A.I.dvisor indicates that over the last year, LYEL has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LYEL jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To LYEL | 1D Price Change % | ||
|---|---|---|---|---|
| LYEL | 100% | -2.34% | ||
| VCYT - LYEL | 46% Loosely correlated | -4.14% | ||
| ABEO - LYEL | 44% Loosely correlated | -4.61% | ||
| SLDB - LYEL | 44% Loosely correlated | -2.97% | ||
| EDIT - LYEL | 43% Loosely correlated | -8.87% | ||
| TSHA - LYEL | 43% Loosely correlated | -2.13% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ETHD | 34.36 | 2.86 | +9.08% |
| ProShares UltraShort Ether ETF (ETHD) | |||
| GMOI | 40.30 | -0.04 | -0.11% |
| GMO International Value ETF | |||
| SPRE | 18.58 | -0.12 | -0.64% |
| SP Funds S&P Global REIT Sharia ETF (SPRE) | |||
| JIRE | 81.51 | -0.80 | -0.97% |
| JPMorgan International Research Enhanced Equity ETF (JIRE) | |||
| TEMX | 32.79 | -2.18 | -6.22% |
| Touchstone Sands Capital Emerging Markets ex-China Growth ETF (TEMX) | |||